Unmoderated Poster Presentations
| P001 Hypofractionation vs. conventional fractionation radiotherapy in patients with high risk prostate cancer: Early results of a phase III randomized study S. Arcangeli, Rome (IT) |  | |
| P002 Ahistone deacetylase inhibitor belinostat (pxd-101) represses androgen receptor expression and acts synergistically with castration and bicalutamide treatment to inhibit prostate cancer growth in hormone refractory models C. Festuccia, L'aquila (IT) | ||
| P003 The first set of nomograms predicting late rectal toxicity in prostate cancer patients undergoing 3DCRT: Development and internal validation T. Rancati, Milano (IT) | | |
| P004 Long-term safety and tolerability of abiraterone acetate (AA) in advanced castration resistant prostate cancer (CRPC) D. Bianchini, Surrey (GB) | | |
| P005 Molecular genetic alterations and their predictive values in superficial bladder cancer A. Babayan, Moscow (RU) | | |
| P006 Paclitaxel plus hyaluronic acid for intravesical therapy of carcinoma in situ of the bladder refractory bcg treatment: Preliminary results of a phase i study M. Racioppi, Rome (IT) | | |
| P007 Micropapillary urothelial carcinoma of the urinary bladder: Early radical surgery or neoadjuvant chemotherapy? A. Fergany, Cleveland (US) | | |
| P008 A randomized prospective phase II study with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first-line treatment in advanced renal cell cancer (RCC): ROSORC trial G. Procopio, Milan (IT) | | |
| P009 Accelerated growth of renal carcinoma cells after radiofrequency ablation S.G.C. Kroeze, Utrecht (NL) | | |
| P010 Assessment of quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib in a phase III double-blind, placebo-controlled trial R. Hawkins, Manchester (GB) | | |
| P011 Efficacy of transrectal power doppler sonography in identification of extraprostatic extension | ||
| P012 The predictors of significant Gleason upgrading in patients with low-risk prostate cancer | ||
| P013 MR spectroscopic imaging in patients with previous negative transrectal prostatic biopsies. A preliminary clinicopathologic study | | |
| P014 [18F]-fluorocholine PET/CT for preoperative lymph node staging of prostate cancer. Preliminary results of a prospective study | | |
| P015 Stage migration in patients with clinically localized prostate cancer underwent radical prostatectomy | | |
| P016 Indication for lymphadenectomy in localised prostate cancer can no longer be based on the Partin tables | | |
| P017 African American men ≥ 75 years old with a baseline of PSA < 6.0 ng/ml may safely stop PSA screening | | |
| P018 Comparison between morphologic, spectroscopic and dynamic contrast enhancement evaluation of endorectal coil magnetic resonance sequences in patients with elevated prostatic specific antigen (PSA) level and previous negative biopsy | | |
| P019 GSTP1 hypermethylation, as a biomarker in the diagnosis of prostatic cancer | ||
| P020 Prognostic factors of low volume prostate cancer in patients underwent radical prostatectomy | | |
| P021 Prior TUR of the prostate should not be a contra-indication for prostate seed brachytherapy | | |
| P022 Short-term outcome after high-intensity focused ultrasound in the treatment of patients with prostate cancer | | |
| P023 Dosimetric comparison of classical Iodine-125 low dose rate prostate brachytherapy plans versus hybrid plans with two seed activities | | |
| P024 Acute and subacute toxicities in prostate cancer patients with fiducial marker image-guided radiotherapy | | |
| P025 Prostate seed implants alone for low-and intermediate risk prostate cancer - results from the Europe Hospitals Brussels | | |
| P026 Hypofractionated stereotactic body radiation therapy for clinically localized prostate cancer | | |
| P027 Median 5 year follow-up of Iodine 125 brachytherapy (BT) as monotherapy in men aged 55 years and under with favorable prostate cancer | | |
| P028 Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression free survival - results of a retrospective study | | |
| P029 Late hematuria after high-dose conformal radiotherapy in prostate cancer | | |
| P030 Cyberknife stereotactic radiotherapy as monotherapy for early stage prostate cancer: Early toxicity | | |
| P031 Correlation between prostate brachytherapy related urethral stricture and urethral dosimetry: A matched case control study | | |
| P032 Image guided intensive modulated radiosurgery boost combined with conformal radiotherapy prostate cancer patients | | |
| P033 Combined schedule - external beam radiotherapy (EBRT) with high-dose rate brachytherapy (HDR-BT) boost vs. high-dose EBRT in treatment of patients with prostate cancer | | |
| P034 Comparison of bone alignment and fiducial markers alignment for online cone-beam ct-guided radiation therapy of prostate cancer | ||
| P035 A matched-control analysis of adjuvant and salvage postoperative intensity-modulated radiotherapy for pT3-4N0 prostate cancer | ||
| P036 Renal cysts: Imaging at contrast-enhanced ultrasound (CE-US) and correlation with computed tomography (CT) | | |
| P037 Positive surgical margins in radical prostatectomy | | |
| P038 HER-2/neu and Androgen Receptor in TRUS of clinically localized prostate cancer identifies patients at risk of metastasis. Experience at NCI, Cairo Egypt | | |
| P039 Prognostic significance of perineural invasion (PNI) on biochemical outcome following 125I prostate brachytherapy (BT) | | |
| P040 Impact of Tyrosin Kinase Inhibitors (TKIs) in the treatment of patients with advanced renal cell carcinoma (RCC): A single centre retrospective review | | |
| P041 Prospective study of radiotherapy toxicity associated with the use of hypofractionated 57Gy in 19 fraction external beam radiotherapy to the prostate | | |
| P042 Radical prostatectomy over the past two decades: Duke’s experience in 4196 cases | ||
| P043 Measures of genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer | ||
| P044 Patient satisfaction & Global HRQL after LDR-brachytherapy for localized prostate cancer | | |
| P045 Obese African Americans with diagnostic PSA | ||
| P046 C-11 choline PET/CT for predicting local recurrence of prostate cancer after radical prostatectomy | | |
| P047 Docetaxel in metastatic hormone refractory prostate cancer (mHRPC): A prospective audit | | |
| P048 Hypofractionation vs. conventional fractionation radiotherapy in patients with high risk prostate cancer: Analysis of acute and late toxicity | | |
| P049 Choline PET/CT for detecting of local recurrence in prostate cancer | | |
| P050 In vitro radiosensityzing effects of phosphorothioate antisense oligonucleotide (g3139, genasense) in preclinical models of prostate cancer | ||
| P051 Radiotherapy in locally advanced prostate cancer. Our department experience | | |
| P052 Interfraction displacements of the prostate during an imrt session: What margins do we need? | | |
| P053 Combined radiotherapy of prostate cancer | | |
| P054 High-dose 3D-Conformal radiotherapy (HD-3D-CRT) or Low-dose 3D-Conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) as dose escalation for intermediate–or high-risk prostate cancer: Early results of a prospective comparative trial | ||
| P055 Does igrt-imrt improve toxicity profile in prostate advanced cancer? | | |
| P056 New triptorelin 6-month formulation shows high level of efficacy and safety in patients with advanced prostate cancer | | |
| P057 Prevention of skeletal-related events in patients with prostate cancer and bone metastases: Comparisons of the cost-effectiveness of zoledronic acid in France, Germany, Portugal, and the Netherlands | | |
| P058 High risk prostate cancer (Gleason score ≥ 8 and/or PSA ≥ 20 ng/mL): What is the role of radiation therapy associated with hormonal therapy? | | |
| P059 5 year outcome of post-prostatectomy radiotherapy: A single institution's review | | |
| P060 Hormone naive patients with advanced prostate cancer have lower initial BMD than healthy control | | |
| P061 ERK-1 and ERK-2 expression is related to serum prostate specific antigen (PSA) levels and prostate cancer progression | | |
| P062 Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer | | |
| P063 Molecular treatment of advanced prostate cancer (PCA) by the mammalian target of rapamycin (mTOR) inhibitor RAD001 | | |
| P064 NF-kB (p50/p65): A relation with serum PSA levels and prostate cancer progression | | |
| P065 How to improve the reconstruction of prostate MRI imaging to transrectal ultrasound imaging? | ||
| P066 Pheophorbide A induces the photodynamic cell death in prostate cancer cells | | |
| P067 P-38: Relationship with PSA and possible therapeutic target in prostate cancer | | |
| P068 The effect of combined use of rapamycin and an anti-IGF receptor antibody on prostate cancer cells compared with rapamycin alone | | |
| P069 Autologous tumor cell vaccine: Immunomodulatory effects in patients with prostate cancer | ||
| P070 Implication of ILP and NAIP in prostate cancer development | | |
| P071 Implication of IKB in prostate cancer development | | |
| P072 Prostate cancer development: What is the role of inhibitor of apoptosis proteins (IAPs)? | | |
| P073 Expression of Metalloproteases (MMPs) and their inhibitors (TIMPs) by the different cellular types in prostate carcinoma | | |
| P074 Relationship of the metalloproteases and their inhibitors expression with biochemical recurrence after radical prostatectomy | | |
| P075 Quality of life in patients undergoing active surveillance: Early results | | |
| P076 Active surveillance in low-risk patients with prostate cancer: Preliminary analysis on the correlation between PSA kinetics and histological upsizing/upgrading at re-biopsy | | |
| P077 Toxiciy results and biochemical outcome in patients receiving D90 doses of 180Gy or higher after 125I prostate brachytherapy | | |
| P078 Toxicity is higher in patients receiving adjuvant docetaxel without hormonal treatment after radical prostatectomy for high risk prostate cancer – an initial report from the SPCG 12 study | | |
| P079 Population pharmacokinetic (PK) analysis of a phase II study of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with hormone-resistant prostate cancer (HRPC) and bone metastases | | |
| P080 Sodium butyrate enema in the treatment of acute proctitis following 3dcrt in prostate cancer patients | | |
| P081 Prostatic endorectal magnetic resonance: Recent changes in clinical indications | | |
| P082 Dutasteride lowers the risk of biopsy-detectable prostate cancer among men at increased risk: European sub-analysis from the global REDUCE study | | |
| P083 Preferential resistance of CD45RA- t cells to apoptosis and functional t cell impairment during radiation therapy of prostate cancer | | |
| P084 Lymph node dissection in laparoscopic radical nephrectomy for advanced renal tumours | | |
| P085 A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) | | |
| P086 If we should broaden indications for treatment of T3c renal cell carcinoma with atrial thrombus? | ||
| P087 Cost-effectiveness of zoledronic acid for preventing skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the UK | | |
| P088 Tumor size influence on cancer specific and overall survival after surgical renal carcinoma treatment | | |
| P089 Renal cell carcinoma metastatic to bone: Zoledronic acid and functional independence | | |
| P090 Efficacy and safety of long-term use of Sorafenib (SOR) in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) | | |
| P091 Salvage therapy with sunitinib malate in metastatic renal cell carcinoma (MRCC) patients | | |
| P092 Associations between N-telopeptide of type I collagen (NTX) levels with survival and fractures in patients with bone metastases from renal cell carcinoma (RCC) | | |
| P093 The epidemiology and prognosis of wilms tumor in children, south of Iran. | ||
| P094 Clinical factors associated with outcome in patients with advanced renal cell carcinoma treated with sunitinib | | |
| P095 Changes in lymphocytic populations and autoantibodies resulting from sunitinib treatment of metastatic renal cell carcinoma (mRCC) | | |
| P096 Molecular targeted therapy in advanced renal cancer: Development of molecular predictive biomarkers using a patient RCC-derived murine xenograft model | ||
| P097 A decrease of regulatory T cells correlates with survival after sunitinib-based anti-angiogenic therapy in metastatic renal cancer patients | | |
| P098 BMI and renal cell carcinoma: A meta-analysis | | |
| P099 Intensive intravesical mitomycin c in non muscle-invasive bladder cancer: Preliminary results of neoadiuvant regimen | | |
| P100 Newer therapeutical regimen in intravesical chemotherapy: Intensive mitomycin c | | |
| P101 The safety and efficacy of apaziquone intravesical induction therapy in intermediate risk NMIBC – long term results of a marker lesion study | | |
| P102 Long-term outcome in patients refusing cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: A single institution experience | | |
| P103 Radiotherapy and chemotherapy in bladder cancer. Situation in our radiation oncology department | | |
| P104 Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder | ||
| P105 Long-term results of patients with solitary bladder tumours treated with external beam radiation therapy followed by interstitial brachytherapy | | |
| P106 The use of Lipiodol and Conebeam-CT in deriving patient-specific PTV for bladder image-guided radiotherapy | | |
| P107 The results of radical radiotherapy for non-TCC bladder cancer | ||
| P108 Do smoking cessation programmes have a role in patients with transitional cell carcinoma? | | |
| P109 The practice of the first check cystoscopy following radiotherapy for muscle-invasive bladder cancer: A UK national survey | | |
| P110 Outcomes of surveillance in unselected patients with clinical stage I testicular germ cell tumors: Results of a single institution series | |
